HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)
China · Delayed Price · Currency is CNY 3.650
+0.180 (5.19%)
Sep 30, 2026, 3:04 PM CST
SHE:002437 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 8,139 | 6,852 | 5,677 | 5,517 | 5,583 | 6,397 | |
Market Cap Growth | 16.16% | 20.71% | 2.89% | -1.18% | -12.72% | -9.06% |
Enterprise Value | 7,222 | 6,115 | 5,277 | 5,430 | 5,794 | 6,481 |
Last Close Price | 3.65 | 3.07 | 2.49 | 2.51 | 2.54 | 2.91 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 20.22 | 18.18 | 24.39 | 45.85 | - | 142.01 |
Forward PE | - | 27.91 | 26.21 | 24.55 | 24.55 | 24.55 |
PS Ratio | 3.98 | 3.21 | 2.33 | 2.10 | 1.80 | 2.03 |
PB Ratio | 3.27 | 2.97 | 2.88 | 3.23 | 3.28 | 3.23 |
P/TBV Ratio | 4.16 | 3.89 | 4.01 | 5.01 | 5.36 | 5.36 |
P/FCF Ratio | 28.80 | 27.46 | 16.31 | 22.56 | 24.42 | 26.69 |
P/OCF Ratio | 27.10 | 25.07 | 13.81 | 20.12 | 21.34 | 23.33 |
PEG Ratio | - | 1.37 | 1.37 | 1.37 | 1.37 | 1.37 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.54 | 2.86 | 2.16 | 2.07 | 1.86 | 2.06 |
EV/EBITDA Ratio | 21.63 | 19.13 | 16.67 | 19.65 | 26.87 | 25.45 |
EV/EBIT Ratio | 29.50 | 26.50 | 23.42 | 31.58 | 67.68 | 56.03 |
EV/FCF Ratio | 25.56 | 24.51 | 15.16 | 22.20 | 25.35 | 27.04 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.00 | 0.40 | 0.85 | 0.79 |
Debt / EBITDA Ratio | 0.27 | 0.29 | 0.01 | 2.45 | 6.75 | 5.99 |
Debt / FCF Ratio | 0.31 | 0.37 | 0.01 | 2.76 | 6.37 | 6.50 |
Net Debt / Equity Ratio | -0.38 | -0.36 | -0.26 | -0.02 | 0.10 | 0.03 |
Net Debt / EBITDA Ratio | -2.81 | -2.62 | -1.61 | -0.13 | 0.77 | 0.25 |
Net Debt / FCF Ratio | -3.31 | -3.36 | -1.46 | -0.15 | 0.73 | 0.26 |
Asset Turnover | 0.66 | 0.72 | 0.82 | 0.73 | 0.71 | 0.68 |
Inventory Turnover | 6.24 | 5.93 | 6.00 | 5.42 | 4.81 | 2.30 |
Quick Ratio | 1.58 | 1.36 | 0.80 | 0.67 | 0.67 | 0.68 |
Current Ratio | 1.88 | 1.65 | 1.07 | 0.82 | 0.78 | 0.82 |
Return on Equity (ROE) | 17.87% | 17.86% | 13.17% | 7.54% | -15.72% | 2.75% |
Return on Assets (ROA) | 4.97% | 4.84% | 4.71% | 2.97% | 1.22% | 1.57% |
Return on Invested Capital (ROIC) | 14.91% | 14.67% | 12.27% | 7.06% | 4.38% | 3.27% |
Return on Capital Employed (ROCE) | 9.70% | 9.90% | 11.30% | 9.90% | 4.90% | 5.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.93% | 5.50% | 4.10% | 2.18% | -5.22% | 0.70% |
FCF Yield | 3.47% | 3.64% | 6.13% | 4.43% | 4.09% | 3.75% |
Payout Ratio | 0.37% | 0.32% | 4.02% | 36.41% | - | 157.49% |
Buyback Yield / Dilution | 1.84% | 1.17% | -2.82% | -0.05% | -0.07% | 0.04% |
Total Shareholder Return | 1.84% | 1.17% | -2.82% | -0.05% | -0.07% | 0.04% |